



## PPD Opens Pharmacovigilance and Medical Communications Center in Sofia, Bulgaria

### Reflects PPD's safety and medical communications expertise and growing global demand for these services

**WILMINGTON, N.C.** (May 5, 2010) - PPD, Inc. (Nasdaq: PPD) today announced the opening of a [pharmacovigilance](#) and medical communications center in Sofia, Bulgaria, delivering its full range of drug safety, medical information and medical writing services to meet growing client demand.

"Expanding our safety and medical communications operations in Europe strengthens our ability to bring high quality global health care expertise to provide these services in an efficient, cost-effective and regulatory compliant manner," said Christine Dingivan, M.D., chief medical officer, PPD. "There is strong demand for both pre- and post-approval safety services, and we have an experienced management team on the ground in Bulgaria to oversee our operations and to create customized programs that meet client needs."

PPD will offer [medical information call center](#) support, adverse event capture, safety case processing and reporting, and periodic report writing services from Bulgaria, building upon more than 19 years of safety and medical communications expertise. Sofia will become the company's largest safety center and its third European hub for medical communications contact center services. PPD opened its Athlone, Ireland, facility in March and also operates contact center services in Stockholm, Sweden. This infrastructure gives PPD the capability to provide biopharmaceutical companies with global and regional support for pre- and post-approval drug safety and medical information.

With multiple medical and pharmacy schools in the area, Sofia offers a large pool of highly trained health care professionals with extensive language capabilities. The center employs physicians, pharmacists, nurses and medical specialists who provide safety and medical information support services, including product inquiries, adverse event and product complaint intake, case processing and reporting of drug safety concerns.

PPD has already hired more than 20 employees at the center with plans to expand to more than 200 professionals in the next 12 months.

The U.S. Ambassador to Bulgaria, James Warlick, attended the opening event in Sofia earlier today, stating, "PPD is a leader in its field and has decided to make a significant investment in Bulgaria with its plan to create more than 200 positions in this important technical field." He added, "Bulgaria has a noteworthy and rich history of innovation and technology, and both PPD and the people of Bulgaria can benefit from this venture. The U.S. Embassy looks forward to further strengthening our relationship with PPD as it expands in this region."

PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 41 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit [www.ppd.com](http://www.ppd.com).

*Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the opening of a pharmacovigilance and medical communications and safety center in Sofia, Bulgaria, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; rapid technological advances that make our products and services less competitive; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.*

### Contacts

Media:

Sue Ann Pentecost

+1 919 456 5890

[sueann.pentecost@ppdi.com](mailto:sueann.pentecost@ppdi.com)

Analysts/Investors:

Luke Heagle

+1 910 558 7585

[luke.heagle@ppdi.com](mailto:luke.heagle@ppdi.com)